AbbVie Incurs $216 Million IPR&D Expense in Q3
AbbVie (ABBV) announced that its third-quarter financial results will include a pre-tax expense of $216 million related to acquired in-process research and development (IPR&D) and milestones. This charge is expected to reduce both GAAP and non-GAAP diluted earnings per share by $0.11, impacting the company's reported profitability for the quarter. The IPR&D expenses typically arise from acquisitions where a significant portion of value lies in ongoing research projects without regulatory approval or commercialization yet achieved. This charge reflects AbbVie’s continued investment and integration activities related to its R&D pipeline. Investors may view this as an operational cost rather than a direct loss, but it could affect short-term earnings expectations. The impact on diluted EPS highlights the importance of monitoring such non-cash expenses when evaluating financial performance.
Tickers: $ABBV
Topics: earnings financial results IPR&D expenses